Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07341191 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 4 to 5
  2. Study sites: 3 to 4
    • Eligibility criteria expanded, about 32 words
  3. Start date changed from estimate of Aug 31, 2026 to Aug 24, 2026v7
  4. Start date: Jun 30, 2026 to Aug 31, 2026v6
  5. Study sites: 2 to 3v5
  6. Recruitment opened
    • Start date: Mar 31, 2026 to Jun 30, 2026
    • Study sites: 0 to 2
    v4
  7. 2 versions Re-verified since Feb 11, 2026, no change to tracked fieldsv2-v3
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Trial Details
NCT Number NCT07341191
Lead Sponsor Canadian Cancer Trials Group
Collaborators: BeOne Medicines
Conditions
(from sponsor)		 Mantle Cell Lymphoma
Related terms Lymphoma, Mantle-Cell, Recurrence
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov